Cardiovascular risk assessment

References

• WHO Statistical Report 2006. www.who.int. 2010.
   Google Scholar
• Spence D. Losing the moment. British Medical Journal 2010; 340: c3366–c3367.
   Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–952.
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–2497.
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28(19): 2375–2414.
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105(3): 310–315.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335(7611): 136.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336(7659): 1475–1482.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113(6): 791–798.
   PubMed Web of Science ®Google Scholar
• www.assmann-stiftung.de. 2010.
   Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326(7404): 1419.
   PubMed Web of Science ®Google Scholar
• Lima LM, Carvalho MG, Sousa MO. Apo B/apo A-I ratio and cardiovascular risk prediction. Arq Bras Cardiol 2007; 88(6): e187–e190.
   PubMedGoogle Scholar
• Carnevale Schianca GP, Pedrazzoli R, Onolfo S, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis 2010.
   Google Scholar
• Agoston-Coldea L, Zdrenghea D, Pop D, Craciun A, Rusu ML, Mocan T. Apolipoproteins A-I and B-markers in coronary risk evaluation. Rom J Intern Med 2007; 45(3): 251–258.
   PubMedGoogle Scholar
• Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I—new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis 2007; 17(8): 565–571.
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009; 29(3): 424–430.
   PubMed Web of Science ®Google Scholar
• van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007; 146(9): 640–648.
   PubMed Web of Science ®Google Scholar
• Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151(7): 483–495.
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359(18): 1897–1908.
   PubMed Web of Science ®Google Scholar
• Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis 2008; 196(1): 248–255.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118(22): 2243–51, 4 p.
   Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–2207.
   PubMed Web of Science ®Google Scholar
• Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151(7): 474–482.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733): 2215–2222.
   PubMed Web of Science ®Google Scholar
• Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010; 5(1): 30–36.
   PubMedGoogle Scholar
• Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009; 24(4): 358–363.
   PubMed Web of Science ®Google Scholar
• Ali M, Madjid M. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol 2009; 5(2): 159–173.
   PubMedGoogle Scholar
• Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101(12A): 51F–57F.
   Web of Science ®Google Scholar
• Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation 2010; 121(20): 2235–2248.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300(2): 197–208.
   PubMed Web of Science ®Google Scholar
• Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 2003; 56(9): 880–890.
   PubMed Web of Science ®Google Scholar
• Perrone-Filardi P, Achenbach S, Mohlenkamp S, et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. Eur Heart J 2010.
   Google Scholar
• Bonow RO. Clinical practice. Should coronary calcium screening be used in cardiovascular prevention strategies? N Engl J Med 2009; 361(10): 990–997.
   PubMed Web of Science ®Google Scholar
• Winchester DE, Wymer DC, Shifrin RY, Kraft SM, Hill JA. Responsible use of computed tomography in the evaluation of coronary artery disease and chest pain. Mayo Clin Proc 2010; 85(4): 358–364.
   PubMed Web of Science ®Google Scholar
• Naghavi M, Falk E, Hecht HS, et al. From vulnerable plaque to vulnerable patient—Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006; 98(2A): 2H–15H.
   PubMed Web of Science ®Google Scholar